Rebecca Weil
Corporate Officer/Principal bei OCULIS HOLDING AG
Aktive Positionen von Rebecca Weil
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OCULIS HOLDING AG | Corporate Officer/Principal | 11.09.2023 | - |
Karriereverlauf von Rebecca Weil
Ehemalige bekannte Positionen von Rebecca Weil
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IDORSIA LTD | Vertrieb & Marketing | 01.07.2019 | 01.08.2023 |
SHIRE | Corporate Officer/Principal | 01.08.2016 | 01.03.2019 |
Juvenile Diabetes Research Foundation (New York) | Direktor/Vorstandsmitglied | - | - |
BAUSCH + LOMB CORPORATION | Vertrieb & Marketing | - | - |
NOVARTIS AG | Corporate Officer/Principal | - | - |
ALCON INC. | Corporate Officer/Principal | - | - |
Ausbildung von Rebecca Weil
Massachusetts Institute of Technology | Doctorate Degree |
Princeton University | Undergraduate Degree |
Statistik
International
Schweiz | 5 |
Vereinigte Staaten | 4 |
Irland | 2 |
Operativ
Corporate Officer/Principal | 4 |
Sales & Marketing | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 7 |
Finance | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
OCULIS HOLDING AG | Health Technology |
IDORSIA LTD | Health Technology |
ALCON INC. | Health Technology |
NOVARTIS AG | Health Technology |
BAUSCH + LOMB CORPORATION | Health Technology |
Private Unternehmen | 2 |
---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Juvenile Diabetes Research Foundation (New York) |
- Börse
- Insiders
- Rebecca Weil
- Erfahrung